[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Stoke Therapeutics insider filing: Chief Medical Officer Barry Ticho reported equity awards and acquisitions dated 08/14/2025. The filing shows a direct acquisition of 10,000 shares of common stock at $0, leaving the reporting person with 26,775 shares beneficially owned after the transaction. The filing also reports grants of performance stock units (PSUs) that each convert to one share: an award of 20,000 PSUs granted as restricted stock units upon certification and an award of 10,000 PSUs reported under a separate transaction code. The PSU awards vest in two equal installments, with half vesting on August 14, 2025 and the remainder on August 14, 2026, subject to continued service. All reported derivative holdings and the acquired common shares are shown as direct beneficial ownership.

Positive

• Executive alignment: CMO received 30,000 PSUs that convert to common shares, aligning compensation with company performance and retention.
• Increased insider ownership: Direct acquisition of 10,000 common shares resulted in 26,775 shares beneficially owned after the transaction.
• Clear vesting schedule: PSUs vest in two equal tranches on Aug 14, 2025 and Aug 14, 2026, subject to service and certification.

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine executive equity grants and a nominal share acquisition increase insider alignment without immediate cash consideration.

The filing documents a standard equity-compensation event: a direct acquisition of 10,000 common shares at no cash price and performance-based restricted stock unit grants totaling 30,000 PSUs that convert one-for-one into shares. Vesting is time- and performance-contingent, with half of each award vesting on August 14, 2025 and the remainder on August 14, 2026, contingent on certification and continued service. For investors, this represents management alignment with shareholder outcomes but is a common compensation mechanism rather than a standalone material corporate event.

Corporate Governance Expert

TL;DR: Compensation committee-certified PSUs and a direct share award reflect standard executive remuneration and retention practices.

The disclosure specifies that one PSU equals one share and that the 20,000-unit award was granted upon certification of performance conditions by the compensation committee. Vesting is split over two annual dates, tying retention to continued service. The direct beneficial ownership figures are clearly stated, and there is no indication of indirect holdings or related-party arrangements. This is a routine governance disclosure signaling incentive alignment rather than an extraordinary governance event.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ticho Barry

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2025		M		10,000	A	$0	26,775	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Stock Units	(1)	08/14/2025		A(2)		20,000		(3)	08/14/2026	Common Stock	20,000	$0	20,000	D
Performance Stock Units	(1)	08/14/2025		M			10,000	(3)	08/14/2026	Common Stock	10,000	$0	10,000	D

Explanation of Responses:

1. Each performance stock unit represents a right to receive one share of the Issuer's common stock.

2. This award represents a grant of restricted stock units upon the achievement of certain performance criteria as certified by the Issuer's compensation committee on the Transaction Date.

3. Half the award vests on August 14, 2025 and the remainder shall vest on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

	/s/ Jonathan Allan, Attorney-in-Fact	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for STOK and what is their role?

The Form 4 was filed for Barry Ticho, who is identified as the Chief Medical Officer of Stoke Therapeutics.

What transactions were reported on the 08/14/2025 STOK filing?

The filing reports a direct acquisition of 10,000 common shares at $0 and grants of 20,000 and 10,000 performance stock units on 08/14/2025.

How many shares does the reporting person beneficially own after the transaction?

The reporting person beneficially owned 26,775 common shares following the reported transactions.

What are the vesting terms for the performance stock units?

Each PSU converts to one share. Vesting is split: half vests on August 14, 2025 and the remainder on August 14, 2026, subject to continued service and certification.

Did the filing indicate any indirect beneficial ownership or third-party arrangements?

No. All reported holdings and acquisitions are shown as Direct (D) beneficial ownership in the filing.